Literature DB >> 3776800

Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation.

D Roy, E Marchand, P Gagné, M Chabot, R Cartier.   

Abstract

The medical records of 254 patients with atrial fibrillation were reviewed to determine the incidence of embolic events in relation to type of cardiovascular disease, duration of atrial fibrillation, and use of anticoagulants. During a total follow-up of 833 patient-years in atrial fibrillation, there were 32 instances of systemic embolism: 21 involved the cerebral circulation and 11 were extracerebral. Thirty of these events occurred during 549 patient-years of follow-up without anticoagulation therapy (5.46 of 100 patient-years), while only two embolic events occurred during 284 patient-years on anticoagulants (0.7 of 100 patient-years). Thus, the incidence of embolism was eight times more frequent during the unanticoagulated period of observation in atrial fibrillation (p less than 0.002). The incidence of embolism during follow-up without anticoagulants was the same regardless of the presence or absence of mitral valve disease and regardless of whether atrial fibrillation was chronic or paroxysmal. The rate of serious hemorrhagic complications on anticoagulants was acceptably low (2.11 of 100 patient-years). We conclude that in this study population anticoagulant therapy reduced the risk of embolic complications of atrial fibrillation. The results also indicate that the use of anticoagulants should not be limited to patients with atrial fibrillation due to mitral valve disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3776800     DOI: 10.1016/0002-8703(86)90318-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

Review 1.  Why is warfarin underutilized in patients with atrial fibrillation?

Authors:  Greg C Flaker; John Schutz
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

2.  Stroke risk in AF: do AF patterns matter?

Authors:  Steven A Lubitz; Alisa B Rosen; Patrick T Ellinor; Emelia J Benjamin
Journal:  Eur Heart J       Date:  2010-03-18       Impact factor: 29.983

3.  Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Richard P Whitlock; Jack C Sun; Stephen E Fremes; Fraser D Rubens; Kevin H Teoh
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  [Anticoagulation in atrial fibrillation - an update].

Authors:  Matthias Antz; Bettina Hullmann; Christian Neufert; Wolfgang Vocke
Journal:  Herz       Date:  2008-12       Impact factor: 1.443

5.  Embolic stroke following cardioversion of atrial fibrillation to sinus rhythm with oral amiodarone therapy.

Authors:  R S Yapa; G J Green
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

6.  Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings.

Authors:  H R Andersen; J C Nielsen; P E Thomsen; L Thuesen; A K Pedersen; P T Mortensen; T Vesterlund
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

Review 7.  Challenges in the classification of atrial fibrillation.

Authors:  Steven A Lubitz; Emelia J Benjamin; Jeremy N Ruskin; Valentin Fuster; Patrick T Ellinor
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

Review 8.  Risk-benefit assessment of anticoagulant therapy.

Authors:  R Harrington; J Ansell
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 9.  Role of the new target specific oral anticoagulants in the management of anticoagulation for cardioversion and atrial fibrillation ablation.

Authors:  Marcin Kowalski; Valay Parikh
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

Review 10.  A review of atrial fibrillation.

Authors:  David Dang; Raluca Arimie; L Julian Haywood
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.